Intrathecal urokinase infusion through a microcatheter into the cisterna magna to prevent cerebral vasospasm: experimental study in dogs
Authors:
- 22 July 2008
- book chapter
- Published by Springer Nature
- Vol. 24 (4) , 315-319
Abstract
Our preliminary report on intrathecal urokinase (UK) infusion into the cisterna magna through a microcatheter showed good results in terms of vasospasm prevention in humans. In this study, we evaluated the relationship between different urokinase infusion sites and their effects on vasospasm prevention by using our canine subarachnoid haemorrage (SAH) model. Twenty-four hours after SAH induction, we injected 1000 IU/kg UK into the cisterna magna (CM) or lumbar sac (LS) of dogs by using a microcatheter inserted at the lumbar region. We then obtained serial angiograms and chronologically examined the changes in the mean diameter of the basilar artery (BA) during a 14-day period to determine the effect of the different injection sites on vasospasm prevention. To measure its concentration in the cisterna magna and sylvian fissure, urokinase (1000 IU/kg) was injected into the cisterna magna or lumbar sac of dogs without SAH; measurements were taken at 15-minute intervals until 4 h after injection. Twenty-four hours after injection, urokinase had almost disappeared in the CM group. There was severe and persistent BA constriction in the LS group during the 14-day observation period. In the CM group, the basilar artery was constricted on day 3; however, gradual dilatation occurred over time. The difference between the two groups was significant on days 7, 10, and 14 (P<0.05). In dogs without SAH, the average maximum urokinase concentration in the cisterna magna and the sylvian fissure was 2.5 and 6.7 times higher, respectively, in the cisterna magna group than in the lumbar sac group. In our canine SAH model, the administration of urokinase into the cisterna magna was significantly more effective in preventing cerebral vasospasm than was administration into the lumbar sac. Keywords Cisterna magna subarachnoid haemorrage urokinase vasospasmKeywords
This publication has 18 references indexed in Scilit:
- Microcatheter Intrathecal Urokinase Infusion Into Cisterna Magna for Prevention of Cerebral VasospasmStroke, 2000
- Antisense preproendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhageJournal of Neurosurgery, 1999
- Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhageJournal of Neurosurgery, 1991
- Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhageJournal of Neurosurgery, 1991
- Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhageJournal of Neurosurgery, 1991
- Prevention of vasospasm by clot removal and intrathecal bolus injection of tissue-type plasminogen activatorNeurosurgery, 1991
- Prevention of Vasospasm by Clot Removal and Intrathecal Bolus Injection of Tissue-Type Plasminogen Activator: Preliminary ReportNeurosurgery, 1991
- Intrathecal Irrigation with Urokinase in Ruptured Cerebral Aneurysm CasesNeurologia medico-chirurgica, 1985
- A randomized placebo-controlled double-blind trial of nimodipine after SAH in monkeysJournal of Neurosurgery, 1984
- Relation of Cerebral Vasospasm to Subarachnoid Hemorrhage Visualized by Computerized Tomographic ScanningNeurosurgery, 1980